COSCIENS Biopharma Inc banner

COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.69 CAD -6.6% Market Closed
Market Cap: CA$8.6m

Wall St Price Targets

CSCI Price Targets Summary
COSCIENS Biopharma Inc

There are no price targets for CSCI.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
COSCIENS Biopharma Inc Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
546% Upside
MRVL
Marvell Technology Group Ltd
-40% Downside
ORLY
O'Reilly Automotive Inc
28% Upside
TELA
TELA Bio Inc
155% Upside
MEDP
Medpace Holdings Inc
0% Downside

Revenue
Forecast

3% / Year
Past Growth
-42% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
3% / Year
Past Growth
-42% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 1 year is -42%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-97%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-97%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CSCI's stock price target?
Not Available

CSCI does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for COSCIENS Biopharma Inc?
Projected CAGR
-42%

Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 1 year is -42%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett